CA2275717A1 - Chitosan-gelatin a microparticles - Google Patents

Chitosan-gelatin a microparticles Download PDF

Info

Publication number
CA2275717A1
CA2275717A1 CA002275717A CA2275717A CA2275717A1 CA 2275717 A1 CA2275717 A1 CA 2275717A1 CA 002275717 A CA002275717 A CA 002275717A CA 2275717 A CA2275717 A CA 2275717A CA 2275717 A1 CA2275717 A1 CA 2275717A1
Authority
CA
Canada
Prior art keywords
microparticles
gelatin
chitosan
composition
tosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002275717A
Other languages
French (fr)
Other versions
CA2275717C (en
Inventor
Peter James Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst Uk Limited
Peter James Watts
Lisbeth Illum
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
Archimedes Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Limited, Peter James Watts, Lisbeth Illum, West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited, Archimedes Development Limited filed Critical Danbiosyst Uk Limited
Publication of CA2275717A1 publication Critical patent/CA2275717A1/en
Application granted granted Critical
Publication of CA2275717C publication Critical patent/CA2275717C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Abstract

There is provided a pharmaceutical composition for use in the improved up--take of therapeutic agents across mucosal surfaces which comprises a mixture of chi-tosan and a type A, cationic, gelatin, together with a therapeutic agent. The composition is preferably in the form of microparticles, such as microspheres.
CA002275717A 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles Expired - Fee Related CA2275717C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9700624.1A GB9700624D0 (en) 1997-01-14 1997-01-14 Drug delivery composition
GB9700624.1 1997-01-14
PCT/GB1998/000108 WO1998030207A1 (en) 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles

Publications (2)

Publication Number Publication Date
CA2275717A1 true CA2275717A1 (en) 1998-07-16
CA2275717C CA2275717C (en) 2007-09-11

Family

ID=10805925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002275717A Expired - Fee Related CA2275717C (en) 1997-01-14 1998-01-14 Chitosan-gelatin a microparticles

Country Status (15)

Country Link
US (1) US6465626B1 (en)
EP (1) EP0952822B1 (en)
JP (1) JP2001508061A (en)
AT (1) ATE235889T1 (en)
AU (1) AU725460B2 (en)
CA (1) CA2275717C (en)
DE (1) DE69812887T2 (en)
DK (1) DK0952822T3 (en)
ES (1) ES2200306T3 (en)
GB (2) GB9700624D0 (en)
NO (1) NO993195D0 (en)
NZ (1) NZ335815A (en)
PT (1) PT952822E (en)
WO (1) WO1998030207A1 (en)
ZA (1) ZA98273B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2000004876A2 (en) * 1998-07-23 2000-02-03 Johns Hopkins University School Of Medicine Controlled release of bioactive substances
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
EP1064911B1 (en) * 1999-07-02 2004-02-04 Cognis Iberia, S.L. Microcapsules
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
KR100858945B1 (en) * 2000-06-21 2008-09-17 큐비스트 파마슈티컬즈 인코포레이티드 Compositions and methods to improve the oral absorption of antimicrobial agents
IT1318618B1 (en) * 2000-07-10 2003-08-27 A C R Applied Coating Res S A QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS.
ITMI20010347A1 (en) * 2001-02-21 2002-08-21 Grisotech S A IMMUNOGLOBULIN AND POLYSACCHARID COMPLEXES FOR ORAL ABSORPTION ETRANS-MUCOSAL
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
EP1416916B1 (en) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
EP1443944A1 (en) * 2001-11-12 2004-08-11 Johannes Reinmüller Pharmaceutical applications of hyaluronic acid preparations
ATE508735T1 (en) 2001-12-19 2011-05-15 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
US6830556B2 (en) 2002-01-08 2004-12-14 Zimmer Orthopaedic Surgical Products, Inc. Debridement extension providing irrigation and mechanical scrubbing for removal of dead, devitalized, or contaminated tissue from a wound
WO2003059848A2 (en) * 2002-01-10 2003-07-24 Northeastern University Hybrid immobilized catalytic system with controlled permeability
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
CA2524286A1 (en) * 2003-05-01 2004-11-18 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Li Mited Nasal administration of the lh-rh analog leuprolide
CN101239200A (en) * 2003-06-16 2008-08-13 洛马林达大学医学中心 Deployable multifunctional hemostatic agent
WO2005041811A2 (en) * 2003-06-16 2005-05-12 Loma Linda University Medical Center Deployable hemostatic agent
AU2004253463B2 (en) * 2003-06-16 2010-12-09 Loma Linda University Medical Center Deployable multifunctional hemostatic agent
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
DE10332160A1 (en) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing the dosage form
GB0328186D0 (en) 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
GB0329918D0 (en) 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
JP4694214B2 (en) * 2004-02-20 2011-06-08 ローム株式会社 Comparator, AD conversion circuit, semiconductor device, and imaging device
CN1938036B (en) 2004-02-23 2011-05-11 洛马林达大学医学中心 Hemostatic agent for topical and internal use
JP2007530537A (en) * 2004-03-23 2007-11-01 リートン エンタープライズ，インコーポレーテッド Capsules containing or encapsulating chitosan
US7740883B2 (en) * 2004-03-28 2010-06-22 University Of Debrecen Nanoparticles from chitosan
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
EP1758633B1 (en) * 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Methods for compounding a therapeutic agent to the adventitia of a vessel
GB0416328D0 (en) * 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
WO2006016530A1 (en) 2004-08-10 2006-02-16 Translational Research, Ltd. Transnasal composition having immediate action and high absorbability
DE102004059792A1 (en) 2004-12-10 2006-06-14 Röhm GmbH & Co. KG Multiparticulate dosage form containing mucoadhesively formulated nucleic acid active ingredients, and a method for producing the dosage form
WO2006064331A1 (en) * 2004-12-17 2006-06-22 Medipol Sa Hydrophilic particles based on cationic chitosan derivatives
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US8303972B2 (en) * 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
WO2006118948A2 (en) * 2005-04-29 2006-11-09 Cubist Pharmaceuticals, Inc. Therapeutic compositions
JP2007006849A (en) * 2005-07-04 2007-01-18 Japan Science & Technology Agency Nucleic acid transfection agent consisting of 6-amino-6-deoxychitosan derivative
NZ571965A (en) * 2006-03-30 2012-02-24 Engene Inc Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
EP2612872A3 (en) 2006-06-02 2014-01-22 Synedgen, Inc. Chitosan-Derivative Compounds
WO2007148048A1 (en) 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
JP5415769B2 (en) * 2006-12-26 2014-02-12 株式会社新日本科学 Nasal formulation
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
GB0722507D0 (en) * 2007-11-19 2007-12-27 Zhao Xiaobin Hyaluronic acid personal lubricant
DE102008059857A1 (en) * 2008-12-01 2010-06-02 Forschungsinstitut für Leder und Kunststoffbahnen gGmbH Composition, useful e.g. in molded body, medical technology and packaging for industrial purposes, and as cell growth promoting material and matrix material for cell culture, comprises gelatin, and polysaccharide derivatives, as additives
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2504039A4 (en) 2009-11-25 2014-07-02 Univ Loma Linda Med Chitosan-based hemostatic textile
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CA2833105C (en) * 2011-04-11 2019-04-23 Ayanda Group As Oral pharmaceutical dispersion compositions
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
FR2991172A1 (en) * 2012-06-01 2013-12-06 Galderma Res & Dev TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING MICROCAPSULES
US20140005379A1 (en) 2012-06-20 2014-01-02 Frank GU Nanoparticle delivery system and components thereof
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
AU2019225031B2 (en) * 2018-02-26 2024-04-18 Shin Nippon Biomedical Laboratories, Ltd. Powder preparation, cartridge, and device
EP3813802A4 (en) 2018-06-27 2022-06-08 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN112370437B (en) * 2020-10-20 2022-10-21 好医生药业集团有限公司 Amoxicillin capsule and preparation method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
JPS6034925B2 (en) 1979-07-31 1985-08-12 帝人株式会社 Long-acting nasal preparation and its manufacturing method
CA1219201A (en) 1983-03-07 1987-03-17 Albert E. Chu Microorganism detection test
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
CA2004270A1 (en) * 1988-12-29 1990-06-29 William R. Michael Perfume microcapsules for use in granular detergent compositions
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
BE1003677A3 (en) 1990-01-29 1992-05-19 Schacht Etienne PROCESS FOR THE PREPARATION OF AZOBEVATTENDE POLYMERS AND THEIR USE AS A drug delivery systems.
EP0454444A1 (en) 1990-04-24 1991-10-30 Nissan Chemical Industries Ltd. Glutarimide derivatives and herbicides
CA2042529C (en) 1990-08-10 2002-07-30 Chokyun Rha Polysaccharide article and uses therefor
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
WO1998030207A1 (en) 1998-07-16
ZA98273B (en) 1999-07-13
DK0952822T3 (en) 2003-07-21
ATE235889T1 (en) 2003-04-15
DE69812887T2 (en) 2003-12-18
NO993195L (en) 1999-06-28
ES2200306T3 (en) 2004-03-01
EP0952822A1 (en) 1999-11-03
US6465626B1 (en) 2002-10-15
CA2275717C (en) 2007-09-11
DE69812887D1 (en) 2003-05-08
PT952822E (en) 2003-08-29
AU725460B2 (en) 2000-10-12
GB2335357B (en) 2000-12-13
GB2335357A (en) 1999-09-22
NZ335815A (en) 2001-03-30
NO993195D0 (en) 1999-06-28
EP0952822B1 (en) 2003-04-02
GB9916018D0 (en) 1999-09-08
AU5568998A (en) 1998-08-03
JP2001508061A (en) 2001-06-19
GB9700624D0 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
CA2275717A1 (en) Chitosan-gelatin a microparticles
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
AU2111199A (en) Benzenesulfonamides and benzamides as therapeutic agents
CA2203033A1 (en) Compounds and compositions for delivering active agents
GR3036961T3 (en) N-( 1,2,4] triazoloazinyl)benzenesulfonamide and pyridinesulfonamide compounds and their use as herbicides
IL131163A (en) Heteroaryl-hexanoic acid amide derivatives, their use in the preparation of medicaments, and pharmaceutical compositions comprising them
IL122345A0 (en) Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HK1030543A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
BRPI9810519B1 (en) 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives and pharmaceutical composition comprising the same.
MA26507A1 (en) AEROSOL PHARMACEUTICAL COMPOSITIONS
CA2339765A1 (en) Compounds and compositions for delivering active agents
AU6865298A (en) The use of cryoprotective agent compounds during cryosurgery
IL136941A0 (en) Sulphonamide derivatives and pharmaceutical compositions containing the same
IL136940A0 (en) Sulphonamide derivatives and pharmaceutical compositions containing the same
CA2299366A1 (en) Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases
IL116916A (en) Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same
HK1015351A1 (en) Substituted amino compounds and their use as analgesic active substances
EE04681B1 (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
AU5591296A (en) N-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl)benzamide derivatives, their preparation and their application in therapeutics
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
ZA973016B (en) Transdermally administered acetylcysteine as mucolytic agent.
IL133826A0 (en) Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino] methyl]amino]benzonitrile and pharmaceutical compositions containing the same
PL329596A1 (en) Novel sulphonamide-type compounds, their application in production of pharmaceutic agents and pharmaceutic agent as such

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170116